NCT02575235View on ClinicalTrials.gov

Clinical Trial to Assess the Preventive Effects of Cetylpyridinium Chloride on Sarcopenia

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 1, 2015

Primary Completion Date

July 1, 2016

Study Completion Date

July 1, 2016

Conditions
Sarcopenia
Interventions
DRUG

Cetylpyridinium Chloride (CPC)

Two study groups take CPC of 1.5mg and 4.5mg daily for four weeks.

DRUG

placebo

Control group takes the placebo for the same period.

Trial Locations (1)

Unknown

Seoul National University College of Medicine, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT02575235 - Clinical Trial to Assess the Preventive Effects of Cetylpyridinium Chloride on Sarcopenia | Biotech Hunter | Biotech Hunter